Certificate of Analysis and Data Sheet

Source:

Catalog No.
PRO-371

Background:

MOG peptide (35-55) is highly encephalitogenic and can induce strong T and B cell responses. A single injection of this peptide produces a relapsing- remitting neurologic disease with extensive plaque-like demyelination. Because of the clinical, histophathologic, and immunologic similarities with multiple sclerosis (MS), the MOG induced demyelinating encephalomyelitis may serve as a model for investigating MS.

Description :

MOG is a single, non-glycosylated polypeptide chain containing 21 amino acids and having a molecular mass of 2582 Dalton.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

The protein was lyophilized with no additives.

Solubility:

It is recommended to reconstitute the lyophilized MOG in sterile 18MΩ-cm H₂O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Stability:

Lyophilized MOG although stable at room temperature for 3 weeks, should be stored desiccated below -18⁰C. Upon reconstitution MOG should be stored at 4⁰C between 2-7 days and for future use below -18⁰C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please avoid freeze-thaw cycles.

Purity:

Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.

Amino Acid Composition:

H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH.

Dimers and aggregates:

Less than 1% as determined by silver-stained SDS-PAGE gel analysis.

Protein content:

Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280 nm. 2. Analysis by RP-HPLC, using a calibrated solution of MOG as a Reference Standard.

Usage:

This material is offered by ProSpec-TechnoGene for research, laboratory or further evaluation purposes.

Latest Publications:

1. Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice.
J Neuroimmunol 2005 Dec 28;
2. Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis.
Clin Neurol Neurosurg 2005 Dec 17;
3. Diffusion of sphingomyelin and myelin oligodendrocyte glycoprotein in the membrane of OLN-93 oligodendroglial cells studied by fluorescence correlation spectroscopy.
C R Biol 2005 Dec;328(12):1057-64
4. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.
Eur J Immunol 2005 Nov;35(11):3343-52
5. HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice.
J Neuroimmunol 2005 Dec;169(1-2):1-12
6. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.
Proc Natl Acad Sci U S A 2005 Sep 27;102(39):13992-7